Recent blog posts
NCT07508488 Deucravacitinib Pseudopelade Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07508488 Deucravacitinib Pseudopelade Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07508488 clinical trial report covering Deucravacitinib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07509749 Methylprednisolone Acute Graft Versus Host Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07509749 Methylprednisolone Acute Graft Versus Host Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07509749 clinical trial report covering Methylprednisolone, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07508787 Siplizumab Renal transplant rejection Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07508787 Siplizumab Renal transplant rejection Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07508787 clinical trial report covering Siplizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
ChiCTR2600121825 Eribulin mesylate Advanced HER2-Positive Breast Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
ChiCTR2600121825 Eribulin mesylate Advanced HER2-Positive Breast Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
ChiCTR2600121825 clinical trial report covering Eribulin mesylate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07510217 Dexmedetomidine Hydrochloride Post-Traumatic Headache Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07510217 Dexmedetomidine Hydrochloride Post-Traumatic Headache Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07510217 clinical trial report covering Dexmedetomidine Hydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white spac
Read →
NCT07509086 IL-15-Armored CAR-T(The First Hospital of Jilin University) Multiple Myeloma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07509086 IL-15-Armored CAR-T(The First Hospital of Jilin University) Multiple Myeloma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07509086 clinical trial report covering IL-15-Armored CAR-T(The First Hospital of Jilin University), Phase 2, endpoints, sponsor, geography, readout tim
Read →
NCT07509047 Aluminium Chloride Cholera Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07509047 Aluminium Chloride Cholera Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07509047 clinical trial report covering Aluminium Chloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07509424 Sintilimab Locally Advanced Rectal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07509424 Sintilimab Locally Advanced Rectal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07509424 clinical trial report covering Sintilimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07510334 Ipilimumab Metastatic Clear Cell Renal Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07510334 Ipilimumab Metastatic Clear Cell Renal Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07510334 clinical trial report covering Ipilimumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07509515 QLC5513 Triple Negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07509515 QLC5513 Triple Negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07509515 clinical trial report covering QLC5513, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07510594 Anlotinib Dihydrochloride Large cell neuroendocrine carcinoma of lung Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07510594 Anlotinib Dihydrochloride Large cell neuroendocrine carcinoma of lung Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07510594 clinical trial report covering Anlotinib Dihydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07509892 TQH-3906 Systemic Lupus Erythematosus Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07509892 TQH-3906 Systemic Lupus Erythematosus Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07509892 clinical trial report covering TQH-3906, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →